Advertisement
Advertisement
TNDM
Tandem Diabetes Care, Inc.
20.11
USDSponsored
+0.61
+3.13%
Aug 03, 15:59 UTC -4
Closed
After-Market
19.77
-0.34
-1.72%
TNDM Earnings Reports
Positive Surprise Ratio
TNDM beat 22 of 42 last estimates.
52%
Next Report
In 3 Days
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$260.08M
/-$0.32
Implied change from Q1 26 (Revenue/ EPS)
+5.20%
/+6.67%
Implied change from Q2 25 (Revenue/ EPS)
+8.06%
/-33.33%
Tandem Diabetes Care, Inc. earnings per share and revenue
On May 07, 2026, TNDM reported earnings of -0.30 USD per share (EPS) for Q1 26, beating the estimate of -0.45 USD, resulting in a 33.80% surprise. Revenue reached 247.22 million, compared to an expected 245.95 million, with a 0.52% difference. The market reacted with a -16.19% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 22 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 260.08 million USD, implying an increase of 6.67% EPS, and increase of 5.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
iRadimed Corporation
Report Date
Jul 31, 2026 For Q2 26
Estimate
$0.42
Actual
$0.46
Surprise
+7.38%
Integra LifeSciences Holdings
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.49
Actual
$0.56
Surprise
+13.57%
SI-BONE, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.09
Surprise
+41.02%
Beta Bionics, Inc. Common Stock
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$0.60
Actual
-$0.53
Surprise
+12.77%
ClearPoint Neuro, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.38
Surprise
-29.96%
DexCom, Inc.
Report Date
Jul 30, 2026 For Q1 26
Estimate
$0.62
Actual
$0.70
Surprise
+12.38%
DexCom, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.68
Actual
$0.70
Surprise
+1.92%
Penumbra, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.08
Actual
$0.88
Surprise
-18.96%
Glaukos Corporation
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.14
Surprise
+34.85%
Veracyte, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.24
Actual
$0.31
Surprise
+28.15%
FAQ
What were Tandem Diabetes Care, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Tandem Diabetes Care, Inc. reported EPS of -$0.30, beating estimates by 33.8%, and revenue of $247.22M, 0.52% above expectations.
How did the market react to Tandem Diabetes Care, Inc.'s Q1 2026 earnings?
The stock price moved down -16.19%, changed from $18.47 before the earnings release to $15.48 the day after.
When is Tandem Diabetes Care, Inc. expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Tandem Diabetes Care, Inc.'s next earnings report?
Based on 22
analysts, Tandem Diabetes Care, Inc. is expected to report EPS of -$0.32 and revenue of $260.08M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement